|
|
|
A BILL TO BE ENTITLED
|
|
AN ACT
|
|
relating to the authority of the Cancer Prevention and Research |
|
Institute of Texas to administer the Texas Cancer Clinical Trials |
|
Program. |
|
BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF TEXAS: |
|
SECTION 1. (a) This Act shall be known as the Improve |
|
Patient Access to Cancer Clinical Trials Act. |
|
(b) The legislature finds that: |
|
(1) the ability to translate medical findings from |
|
research to practice relies largely on having robust patient |
|
participation and a diverse participation pool during cancer |
|
clinical trials; |
|
(2) diverse patient participation in cancer clinical |
|
trial depends, in part, on whether a participant can afford |
|
ancillary costs like transportation and lodging during the course |
|
of the patient's participation; |
|
(3) there are significant health disparities that |
|
exist among socioeconomic, racial, ethnic, and regional groups in |
|
Texas; and |
|
(4) this disparity threatens one of the most basic |
|
ethical underpinnings of clinical research, the requirements that |
|
the benefits of research be made available equitably among all |
|
eligible individuals. |
|
(c) It is the intent of the legislature to: |
|
(1) establish a program in the state that encourages |
|
greater patient access to cancer clinical trials; |
|
(2) assist patients facing financial barriers that |
|
inhibit their participation in cancer clinical trials, or assist |
|
patients who have been identified as priorities for health services |
|
to participate in cancer clinical trials by reimbursing direct |
|
patient incurred expenses; and |
|
(3) ensure these trials are widely accessible, improve |
|
the development of therapies, and enhance innovation. |
|
SECTION 2. Chapter 102.051, Health and Safety Code, is |
|
amended to read as follows: |
|
Sec. 102.051. POWERS AND DUTIES. (a) The institute: |
|
(1) may make grants to provide funds to public or |
|
private persons to implement the Texas Cancer Plan, and may make |
|
grants to institutions of learning and to advanced medical research |
|
facilities and collaborations in this state for: |
|
(A) research into the causes of and cures for all |
|
types of cancer in humans; |
|
(B) facilities for use in research into the |
|
causes of and cures for cancer; |
|
(C) research, including translational research, |
|
to develop therapies, protocols, medical pharmaceuticals, or |
|
procedures for the cure or substantial mitigation of all types of |
|
cancer in humans; and
|
|
(D) cancer prevention and control programs in |
|
this state to mitigate the incidence of all types of cancer in |
|
humans; and |
|
(E) programs to encourage access to and |
|
participation in clinical trials and associated research and |
|
community outreach. |
|
|
|
(2) may support institutions of learning and advanced |
|
medical research facilities and collaborations in this state in all |
|
stages in the process of finding the causes of all types of cancer |
|
in humans and developing cures, from laboratory research to |
|
clinical trials and including programs to address the problem of |
|
access to advanced cancer treatment; |
|
(3) may establish the appropriate standards and |
|
oversight bodies to ensure the proper use of funds authorized under |
|
this chapter for cancer research and facilities development; |
|
(4) may employ necessary staff to provide |
|
administrative support; |
|
(5) shall continuously monitor contracts and |
|
agreements authorized by this chapter and ensure that each grant |
|
recipient complies with the terms and conditions of the grant |
|
contract; |
|
(6) shall ensure that all grant proposals comply with |
|
this chapter and rules adopted under this chapter before the |
|
proposals are submitted to the oversight committee for approval; |
|
and |
|
(7) shall establish procedures to document that the |
|
institute, its employees, and its committee members appointed under |
|
this chapter comply with all laws and rules governing the peer |
|
review process and conflicts of interest. |
|
(b) The institute shall work to implement the Texas Cancer |
|
Plan and continually monitor and revise the Texas Cancer Plan as |
|
necessary. |
|
(c) The institute shall employ a chief compliance officer to |
|
monitor and report to the oversight committee regarding compliance |
|
with this chapter and rules adopted under this chapter. |
|
(d) The chief compliance officer shall: |
|
(1) ensure that all grant proposals comply with this |
|
chapter and rules adopted under this chapter before the proposals |
|
are submitted to the oversight committee for approval; and |
|
(2) attend and observe the meetings of the program |
|
integration committee to ensure compliance with this chapter and |
|
rules adopted under this chapter. |
|
SECTION 3. Chapter 102.155, Health and Safety Code, is |
|
amended to read as follows: |
|
Sec. 102.155. AD HOC ADVISORY COMMITTEE. (a) The oversight |
|
committee shall create an ad hoc committees of experts to address |
|
issues including childhood cancers and access to clinical trials. |
|
The oversight committee, as necessary, may create additional ad hoc |
|
committees of experts to advise the oversight committee on issues |
|
relating to cancer. |
|
(b) Ad hoc committee members shall serve for a period |
|
determined by the oversight committee. |
|
SECTION 4. Chapter 102.203, Health and Safety Code, is |
|
amended to read as follows: |
|
Sec. 102.203. AUTHORIZED USE OF FUNDS. (a) A person |
|
awarded money from the cancer prevention and research fund or from |
|
bond proceeds under this subchapter may use the money for research |
|
consistent with the purpose of this chapter and in accordance with a |
|
contract between the person and the institute. |
|
(b) Except as otherwise provided by this section, money |
|
awarded under this subchapter may be used for authorized expenses, |
|
including honoraria, salaries and benefits, travel, conference |
|
fees and expenses, consumable supplies, other operating expenses, |
|
contracted research and development, capital equipment, and |
|
construction or renovation of state or private facilities, and |
|
financial assistance for costs related to participation in |
|
clinical trials such as transportation and lodging. |
|
(c) A person receiving money under this subchapter for |
|
cancer research may not spend more than five percent of the money |
|
for indirect costs. For purposes of this subsection, "indirect |
|
costs" means the expenses of doing business that are not readily |
|
identified with a particular grant, contract, project, function, or |
|
activity, but are necessary for the general operation of the |
|
organization or the performance of the organization's activities. |
|
(d) Not more than five percent of the money awarded under |
|
this subchapter may be used for facility purchase, construction, |
|
remodel, or renovation purposes during any year. Expenditures of |
|
money awarded under this subchapter for facility purchase, |
|
construction, remodel, or renovation projects must benefit cancer |
|
prevention and research. |
|
(e) Not more than 10 percent of the money awarded under this |
|
subchapter may be used for cancer prevention and control programs |
|
during any year. |
|
SECTION 5. This Act takes effect September 1, 2017. |